Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUX-Breast 2
NCT01271725Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2011
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of afatinib in HER2-positive breast cancer, sponsored by Boehringer Ingelheim. Started May 2011; status: completed.
02
Drugs
afatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01271725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01271725.